Characterisation of blood cell aggregates in viral and bacterial ARDS using digital holographic microscopy

Characterisation of blood cell aggregates in viral and bacterial ARDS using digital holographic microscopy - AGGREGARDS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031673

Enrollment

Registered

2023-05-02

Start date

2023-01-14

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J80

Interventions

Group 1: bacterial ARDS: Assessment of clinical, laborchemical and imaging data from the medical chart, assessment of blood cells and aggregates using digital holographic microscopy (DHM) and assessme

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - mechanical ventilation - meeting the criteria of one of the following subgroups (retrospective re-assignment possible) 1. bacterial ARDS (according to Berlin-Definition of ARDS and typical radiological finding or pathogen detected in respiratory specimen) 2. viral ARDS (according to Berlin-Definition of ARDS and molecular detection in respiratory specimen) 3. lack of viral/bacterial infection and no evidence of systemic infection in clinically/laboratory investigation

Exclusion criteria

Exclusion criteria: - allocation to one of the subgroups impossible

Design outcomes

Primary

Measure	Time frame
- blood cell aggregates (assessed using DHM within 48h from intubation or ARDS diagnosis (t0), on day 2-4 (t1) and on day 5-7 (t2) if still hospitalized, once before discharge (tf), and in ICU patients every 3-4 days) - antigen- and cell-specific cytokine release (using flow cytometry upon stimulation within 48h from intubation or ARDS diagnosis (t0), on day 2-4 (t1) and on day 5-7 (t2) if still hospitalized)	—

Measure

Time frame

- blood cell aggregates (assessed using DHM within 48h from intubation or ARDS diagnosis (t0), on day 2-4 (t1) and on day 5-7 (t2) if still hospitalized, once before discharge (tf), and in ICU patients every 3-4 days) - antigen- and cell-specific cytokine release (using flow cytometry upon stimulation within 48h from intubation or ARDS diagnosis (t0), on day 2-4 (t1) and on day 5-7 (t2) if still hospitalized)

—

Secondary

Measure	Time frame
- cell granularity - mortality - ventilator-free days within the first 28 days on ICU - oxygenation index - Extravascular lung water index (EVLWI) - superinfection	—

Countries

Germany

Contacts

Public ContactSebastian Rasch

Klinikum rechts der Isar

sebastian.rasch@mri.tum.de089-4140-9352

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026